Third-line multiple myeloma treatment of inpatients in a German cancer center: analysis of potential cost savings due to decreased renal insufficiency

Third-line multiple myeloma treatment of inpatients in a German cancer center: analysis of potential cost savings due to decreased renal insufficiency

Abstract Background Renal insufficiency is one of the most common complications in the treatment of multiple myeloma (MM). The administration of isatuximab showed improved patient outcome regarding the occurrence of renal insufficiency. Building on the results of the ICARIA-MM study, the aim of this...

Full description

Saved in:
Bibliographic Details
Main Authors: F. Jakobs, P. Ahmadi, V. Osterkamp, J. Jeck, U. Holtick, C. Scheid, Florian Kron
Format: Article
Language:English
Published: BMC 2025-03-01
Series:Cost Effectiveness and Resource Allocation
Subjects:
Multiple myeloma
Renal insufficiency
Cost savings
Isatuximab
Hospital management
Online Access:https://doi.org/10.1186/s12962-024-00600-w
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12962-024-00600-w

Similar Items